CRSP,ADRX Stock Price and Quote

Peers: BEAM NTLA EDIT PRME VRTX IONS VIR ALNY INCY WVE

| Held by: ARKE ARKK XBI IWM ARKG VXF IWN IBB VTWO SCHA

Index	RUT
Market Cap	4.81B
Enterprise Value	3.23B
Income	-451.14M
Sales	13.39M
Book/sh	18.07
Cash/sh	24.46
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Oct 19, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	359.34
P/B	2.75
P/C	2.03
P/FCF	-
EV/EBITDA	-
EV/Sales	241.27
Quick Ratio	17.85
Current Ratio	17.85
Debt/Eq	0.45
LT Debt/Eq	0.44
Option/Short	Yes / Yes

EPS (ttm)	-4.76
EPS next Y	-3.33
EPS next Q	-1.04
EPS this Y	32.62%
EPS next Y	23.70%
EPS next 5Y	32.28%
EPS past 3/5Y	8.21% -4.10%
Sales past 3/5Y	43.09% 37.31%
EPS Y/Y TTM	12.20%
Sales Y/Y TTM	-64.80%
EPS Q/Q	60.57%
Sales Q/Q	1041.37%
Earnings	Aug 03 AMC
EPS/Sales Surpr.	21.31% 36.69%

Insider Own	7.16%
Insider Trans	-1.39%
Inst Own	73.20%
Inst Trans	-1.39%
ROA	-19.28%
ROE	-26.09%
ROIC	-17.96%
Gross Margin	-1510.66%
Oper. Margin	-3971.53%
Profit Margin	-3368.72%
SMA20	-4.91%
SMA50	-8.81%
SMA200	-6.07%
Trades

Shs Outstand	96.66M
Shs Float	89.77M
Short Float	20.81%
Short Ratio	12.01
Short Interest	18.68M
52W High	68.71 -27.58%
52W Low	44.12 12.79%
Volatility	3.94% 5.07%
ATR (14)	2.43
RSI (14)	41.42
Beta	1.91
Rel Volume	0.04
Avg Volume	1.56M
Volume	3,455

Perf Week	1.04%
Perf Month	-10.66%
Perf Quarter	6.49%
Perf Half Y	2.00%
Perf YTD	-5.11%
Perf Year	-25.96%
Perf 3Y	24.09%
Perf 5Y	-47.93%
Perf 10Y	260.07%
Recom	1.87
Target Price	82.95
Prev Close	49.99
Price	49.76
Change %	-0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-26	Initiated	UBS	Neutral	$52
Jun-11-26	Resumed	Morgan Stanley	Equal-Weight	$60
Sep-18-25	Initiated	JP Morgan	Overweight	$70
Feb-14-25	Upgrade	Evercore ISI	In-line → Outperform	$60 → $99
Feb-12-25	Upgrade	TD Cowen	Sell → Hold	$35
Feb-03-25	Initiated	H.C. Wainwright	Buy	$65
Aug-06-24	Reiterated	Needham	Buy	$88 → $84
Aug-02-24	Initiated	Rodman & Renshaw	Buy	$90
Jun-28-24	Resumed	Guggenheim	Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-11-23	Downgrade	TD Cowen	Market Perform → Underperform	$30
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy	$82
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform	$75
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight	$72
Mar-21-23	Initiated	Bernstein	Mkt Perform	$44
Mar-17-23	Initiated	Bryan Garnier	Buy	$70
Mar-07-23	Initiated	Robert W. Baird	Neutral	$46
Oct-11-22	Initiated	Morgan Stanley	Underweight	$37

Show Previous Ratings

Oct-19-26 04:05PM	CRISPR Therapeutics Announces Chief Financial Officer Transition (GlobeNewswire)
Oct-08-26 08:30AM	CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026 (GlobeNewswire)
Oct-06-26 12:40PM	3 Trending Names Overtaking Wall Street Today (Schaeffer's Research) -5.82%
Oct-02-26 10:15AM	CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 (GlobeNewswire)
Sep-24-26 08:46AM	Anthropic AI Discovery Gene-Editing Stocks Falling (GuruFocus.com)
05:49PM	Loading…
Sep-23-26 05:49PM	CRSP, NTLA, BEAM, PRME, EDIT Shares Slip Did Claude Just Spook Gene-Editing Stocks? (Stocktwits) -5.54%
Sep-17-26 04:11PM	Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout (Investor's Business Daily) +9.80%
Sep-08-26 08:30AM	CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Sep-02-26 08:32AM	Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive)
Sep-01-26 03:59PM	Investors Shrug Off Good News for Heart Patients From New Meds (Barrons.com)
Aug-28-26 10:31AM	CRISPR Therapeutics Presents Phase 1a Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 (GlobeNewswire)
Aug-03-26 06:19PM	CRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2 (Stocktwits) +7.06%
04:15PM	CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-27-26 04:08PM	Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com)
Jul-16-26 09:06AM	Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis) -5.45%
08:48AM	Loading…
Jul-08-26 08:48AM	Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis)
Jul-07-26 01:05PM	Progress Report: How Our Top Stock Picks of 2026 Are Faring (Schaeffer's Research)
Jul-02-26 05:16PM	CRSP, VRTX Stocks Surge As FDA Clears Casgevy For Children Ages 2 And Up (Stocktwits) +8.02%
Jun-24-26 07:00AM	3 Companies Redefining Healthcare Innovation (ETF Trends)
May-28-26 08:00AM	CRISPR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.32%
May-06-26 08:30AM	CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference (GlobeNewswire) +5.15%
May-04-26 04:30PM	CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-10-26 01:55PM	This Nuclear Stock Had Its Best Day Ever. Cathie Wood's ARK Took the Moment to Sell. (Barrons.com)
Apr-07-26 08:00AM	CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-26 12:44PM	Cathie Wood Dumps $2.1 Million in This 'Magnificent Seven' Stock (GuruFocus.com)
Mar-24-26 11:05AM	Anti-Aging Protein Research Takes a Step Forward with Cell Cloning (PR Newswire)
Mar-11-26 07:00AM	CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering (GlobeNewswire) -5.44%
Mar-10-26 12:56PM	What's Going On With CRISPR Therapeutics Stock Today? (Benzinga) -10.17%
08:04AM	Here is Why CRISPR Therapeutics (CRSP) Appears so Good (Insider Monkey)
07:00AM	CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering (GlobeNewswire)
01:32PM	Loading…
Mar-09-26 01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga)
Mar-08-26 09:03PM	CRISPR Therapeutics Pivots Beyond Casgevy, Highlights CTX310 Data and New Cardiovascular Push (MarketBeat)
Mar-07-26 07:10AM	CRISPR Therapeutics AG (CRSP) a Moderate Buy, Per Wall Street (Insider Monkey)
Mar-02-26 09:00AM	Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock (Zacks)
Feb-28-26 02:21AM	Here's What Analysts Are Saying About CRISPR Therapeutics AG (CRSP) (Insider Monkey)
Feb-25-26 09:00AM	Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 (PR Newswire)
Feb-24-26 06:44PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research) +5.17%
01:14PM	CRISPR Therapeutics Stock Sees RS Rating Rise To 73 (Investor's Business Daily)
Feb-20-26 10:48AM	Genomics Stocks That Deserve a Place in Your Portfolio in 2026 (Zacks)
Feb-19-26 12:32PM	CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows (MarketBeat)
07:16AM	CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit (MarketBeat)
Feb-17-26 04:58PM	Cathie Wood Buys COIN, HOOD (GuruFocus.com)
04:17PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Feb-15-26 11:33PM	Cathie Wood buys $46 million of tumbling tech stock (TheStreet)
Feb-14-26 09:06AM	Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI (TipRanks)
09:05AM	Crispr Therapeutics price target raised to $82 from $80 at Needham (TipRanks)
Feb-13-26 01:45PM	CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens (Benzinga) +8.46%
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
08:00AM	Vertexs CRISPR therapy rebounds in latest earnings (BioPharma Dive)
Feb-12-26 06:00PM	CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:30PM	CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-10-26 10:45AM	Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks)
Feb-09-26 10:22AM	Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect (Zacks)
Feb-06-26 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks) +6.23%
Feb-05-26 07:28PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research) -8.55%
10:00AM	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
07:19AM	Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline (Insider Monkey)
Feb-04-26 06:52PM	Blue Bird Q1 Earnings Call Highlights (MarketBeat)
Feb-03-26 10:00AM	CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:30AM	CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-02-26 05:50PM	CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Jan-30-26 08:07AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) -6.35%
07:06AM	Cathie Wood Doubles Down on Joby Aviation After Stock Crashes 17% (GuruFocus.com)
Jan-29-26 12:48PM	Forget AI Stocks: This Biotech Could Cure What AI Can't Touch (Motley Fool)
07:18AM	BofA is Bullish on CRISPR Therapeutics AG (CRSP) (Insider Monkey)
Jan-27-26 04:33AM	Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops (Benzinga)
Jan-26-26 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why (Zacks)
09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jan-23-26 06:00PM	CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors (Zacks) -8.70%
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga) +11.11%
Jan-20-26 12:05AM	Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? (Benzinga)
Jan-18-26 12:00PM	3 Seasonal Stocks to Buy Immediately (InvestorPlace)
Jan-15-26 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jan-13-26 09:00AM	Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know (Zacks)
Jan-12-26 12:05PM	2 Biotech Stocks That Could Soar This Year (Motley Fool)
09:30AM	CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
08:36AM	CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones (GlobeNewswire)
Jan-09-26 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Jan-06-26 07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks) +5.51%
Jan-05-26 06:00PM	CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why (Zacks)
08:30AM	CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 01:29PM	Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize (PR Newswire)
Dec-31-25 09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
Dec-30-25 11:49PM	Chardan Maintains A Buy Recommendation On CRISPR Therapeutics AG (CRSP) (Insider Monkey)
05:50PM	CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
09:00AM	Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock (Zacks)
07:40AM	Contrarius Global Equity Fund's Thoughts on CRISPR Therapeutics' (CRSP) Gene Editing Therapy (Insider Monkey)
Dec-29-25 12:51PM	TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock (GuruFocus.com)
Dec-28-25 10:05AM	CRISPR Therapeutics Reports Strong 90% Response Rate and Lupus Remission in Landmark Zugo-Cel Update (Insider Monkey)
Dec-27-25 01:15PM	Cathie Wood drops $1.3 million on healthcare stock (TheStreet)
Dec-26-25 10:56AM	Cathie Wood Doubles Down on Self-Driving and Gene-Editing Stocks Ahead of 2026 (GuruFocus.com)
06:20AM	These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? (Motley Fool)
Dec-24-25 04:35AM	Is CRISPR Therapeutics Stock Yesterday's News? (Motley Fool)
Dec-23-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
02:38PM	3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term (Motley Fool)
10:35AM	CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies (Zacks)
Dec-22-25 08:30AM	CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kulkarni Samarth	Chief Executive Officer	Oct 19 '26	Sale	49.78	47,837	2,381,326	311,899	Oct 20 05:35 PM
George Simeon	Director	Oct 14 '26	Option Exercise	14.00	30,000	420,000	30,000	Oct 16 05:45 PM
George Simeon	Director	Oct 14 '26	Sale	49.63	14,514	720,373	15,486	Oct 16 05:45 PM
KASINGER JAMES R.	General Counsel and Secretary	Oct 14 '26	Sale	49.26	1,040	51,230	95,857	Oct 15 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Oct 14 '26	Sale	49.26	4,098	201,867	259,736	Oct 15 05:35 PM
SIMEON GEORGE	Director	Oct 14 '26	Proposed Sale	49.63	14,514	720,373		Oct 14 04:16 PM
KASINGER JAMES R.	General Counsel and Secretary	Oct 06 '26	Option Exercise	13.62	1,990	27,104	96,774	Oct 08 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Oct 06 '26	Sale	60.04	1,990	119,481	94,784	Oct 08 05:35 PM
JAMES KASINGER	Officer	Oct 06 '26	Proposed Sale	60.04	1,990	119,481		Oct 06 04:47 PM
KASINGER JAMES R.	General Counsel and Secretary	Sep 22 '26	Option Exercise	13.62	10,400	141,648	105,184	Sep 24 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Sep 22 '26	Sale	60.24	10,400	626,460	94,784	Sep 24 05:35 PM
JAMES KASINGER	Officer	Sep 22 '26	Proposed Sale	60.24	10,400	626,460		Sep 22 04:42 PM
Behbahani Ali	Director	Sep 17 '26	Option Exercise	14.00	30,000	420,000	30,316	Sep 21 06:40 PM
Behbahani Ali	Director	Sep 17 '26	Sale	57.09	13,679	780,935	16,637	Sep 21 06:40 PM
ALI BEHBAHANI	Director	Sep 17 '26	Proposed Sale	57.09	13,679	780,935		Sep 17 04:08 PM
Patel Naimish	Chief Medical Officer	May 29 '26	Sale	55.62	3,786	210,577	19,357	Jun 01 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 23 '26	Sale	46.78	3,182	148,854	94,308	Mar 24 05:38 PM
Kulkarni Samarth	Chief Executive Officer	Mar 23 '26	Sale	46.78	10,020	468,736	255,501	Mar 24 05:37 PM
Prasad Raju	Chief Financial Officer	Mar 23 '26	Sale	46.78	3,708	173,460	15,565	Mar 24 05:37 PM
Patel Naimish	Chief Medical Officer	Mar 16 '26	Sale	48.26	3,150	152,019	13,143	Mar 17 05:37 PM
Prasad Raju	Chief Financial Officer	Mar 16 '26	Sale	48.26	9,869	476,278	13,773	Mar 17 05:37 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 16 '26	Sale	48.26	3,450	166,497	91,240	Mar 17 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Mar 16 '26	Sale	48.26	10,349	499,443	245,834	Mar 17 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 11 '26	Sale	52.80	2,800	147,840	87,815	Mar 12 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Mar 11 '26	Sale	52.80	9,798	517,334	235,558	Mar 12 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 19 '26	Sale	52.58	6,967	366,325	226,106	Feb 20 05:36 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 19 '26	Sale	52.58	2,112	111,049	85,115	Feb 20 05:35 PM
Prasad Raju	Chief Financial Officer	Jan 22 '26	Option Exercise	45.15	34,972	1,578,986	41,739	Jan 26 05:35 PM
Prasad Raju	Chief Financial Officer	Jan 22 '26	Sale	60.19	34,972	2,104,965	6,767	Jan 26 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Jan 22 '26	Sale	60.23	60,000	3,613,800	134,201	Jan 22 05:55 PM
Kulkarni Samarth	Chief Executive Officer	Jan 20 '26	Sale	51.75	30,000	1,552,498	194,201	Jan 22 05:55 PM
Samarth Kulkarni	Officer	Jan 22 '26	Proposed Sale	60.81	60,000	3,648,600		Jan 22 05:15 PM
RAJU PRASAD	Officer	Jan 22 '26	Proposed Sale	60.19	34,972	2,105,070		Jan 22 04:03 PM
Samarth Kulkarni	Officer	Jan 20 '26	Proposed Sale	52.61	30,000	1,578,300		Jan 20 05:11 PM
Prasad Raju	Chief Financial Officer	Jan 06 '26	Option Exercise	44.97	29,700	1,335,630	36,467	Jan 08 05:35 PM
Prasad Raju	Chief Financial Officer	Jan 06 '26	Sale	60.16	29,700	1,786,636	6,767	Jan 08 05:35 PM
RAJU PRASAD	Officer	Jan 06 '26	Proposed Sale	60.16	29,700	1,786,636		Jan 06 05:11 PM
Prasad Raju	Chief Financial Officer	Dec 22 '25	Sale	55.95	10,000	559,549	6,767	Dec 23 05:33 PM
RAJU PRASAD	Officer	Dec 22 '25	Proposed Sale	55.95	10,000	559,548		Dec 22 04:20 PM

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CEO & ChairmanDr. Samarth Kulkarni Ph.D.

Chief Financial OfficerDr. Raju Yashaswi Prasad Ph.D.

General Counsel & SecretaryMr. James R. Kasinger J.D.

M.D.Dr. Naimish Patel C.M.

Co-FounderMr. Shaun Foy CFA

ADRX ADARx Pharmaceuticals Inc daily Stock Chart

Peers: ARWR ALNY IONS WVE ABUS DYN STOK SLN VKTX RNA

| Held by: VTI VXF VTWO TMED TDNA VTWG TSEE VTWV

Index	-
Market Cap	1.96B
Enterprise Value	1.90B
Income	-
Sales	-
Book/sh	-2.35
Cash/sh	3.85
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Sep 25, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	4.59
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.98
Current Ratio	12.98
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.82
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	- -

Insider Own	59.08%
Insider Trans	8.56%
Inst Own	-
Inst Trans	12.57%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.70%
SMA50	-3.70%
SMA200	-3.70%
Trades

Shs Outstand	106.80M
Shs Float	45.36M
Short Float	2.56%
Short Ratio	1.41
Short Interest	1.16M
52W High	23.21 -23.83%
52W Low	16.61 6.44%
Volatility	7.28% -
ATR (14)	1.63
RSI (14)	41.10
Beta	-
Rel Volume	0.00
Avg Volume	825.58K
Volume	0

Perf Week	-0.11%
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-20.00%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	34.25
Prev Close	17.68
Price	17.68
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-26	Initiated	UBS	Buy	$35
Oct-20-26	Initiated	TD Cowen	Buy
Oct-20-26	Initiated	Morgan Stanley	Overweight	$32
Oct-20-26	Initiated	JP Morgan	Overweight	$38

Oct-01-26 04:15PM

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering

(GlobeNewswire) -6.60%

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chimovits Erez	Director	Sep 28 '26	Buy	17.00	61,516	1,045,772	9,292,025	Sep 30 05:29 PM
GORDON CARL L	Director	Sep 28 '26	Buy	17.00	950,000	16,150,000	14,325,529	Sep 30 05:25 PM
ORBIMED ADVISORS LLC	Director	Sep 28 '26	Buy	17.00	950,000	16,150,000	14,325,529	Sep 30 05:23 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 28 '26	Buy	17.00	1,600,000	27,200,000	5,554,094	Sep 29 09:45 PM
George Simeon	Director	Sep 28 '26	Buy	17.00	1,600,000	27,200,000	5,554,094	Sep 29 09:43 PM

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.

Co-FounderDr. Zhen Li Ph.D.

Chief Scientific OfficerDr. A. Robert MacLeod Ph.D.

CFO & Chief Business OfficerMr. Ryan Fisk M.B.A.

Ph.D.Dr. Christopher Claeboe M.B.A.

Chief Technology OfficerDr. Rui Zhu Ph.D.

CRSP

CRISPR Therapeutics AG

ADRX

ADARx Pharmaceuticals Inc

Upgrade your Finviz experience